Search

AF solution

Chevron

Cutting-Edge Scientific Breakthroughs: Blood Stem Cells, Genetic Alphabet Expansion, CRISPR Therapies, and Advances in Neurotechnology

FDA Approves First Monoclonal Antibody for COPD

Journal: Nature Reviews Drug Discovery

Author: Asher Mullard, USA

This paper discusses the FDA approval of dupilumab (Dupixent), the first monoclonal antibody for treating chronic obstructive pulmonary disease (COPD). The drug, developed by Regeneron and Sanofi, targets patients with an eosinophilic phenotype and is expected to benefit around 300,000 adults in the U.S.

Expanding the Genetic Alphabet to Create New Proteins

Journal: Science

Author: Dr. Floyd Romesberg, The Scripps Research Institute, USA

Scientists from the Scripps Research Institute have expanded the genetic alphabet to create novel proteins, enabling easier addition of non-canonical amino acids to proteins. This development enhances our ability to design new proteins with potential applications in drug development and protein engineering.

CRISPR-Based Gene Editing Therapies in Clinical Trials

Journal: Nature Medicine

Author: Dr. Jennifer Doudna, University of California, Berkeley, USA

The potential for CRISPR-based therapies to treat a variety of genetic conditions has profound implications. As these therapies are refined, they could lead to more effective treatments for diseases like cancers and genetic disorders .

Neurotechnology race ramps up, but fundamental questions remain

Journal: Nature

Author: Bec Crew, Senior Editor, Nature Index, USA

With rapid advancements in neuroscience, AI and brain-computer interface (BCI) technologies are gaining attention for their potential in brain research. However, fundamental questions about how core brain functions operate at cellular and molecular levels remain unresolved. While these technologies are expected to significantly impact the treatment of neurological disorders in the future, more research and funding are required.

Connect with Us

By submitting your details, you confirm that you have reviewed and agree with the Lambda Biologics Privacy Policy.